Shopping Cart 0
Cart Subtotal
USD 0

PTC Therapeutics Inc (PTCT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and commercializes orally active small molecule therapeutics that target post transcriptional control. The company's pipeline products include an orally administered small-molecule targeted at genetic disorders due to a nonsense mutation; an orally active small molecule to reduce the function, activity and amount of BMI1; and an investigational oral therapeutic used for the treatment of spinal muscular atrophy. PTC Therapeutics' ataluren is in phase 3 for the treatment of nonsense mutation duchenne muscular dystrophy.The company works in collaboration with various biotechnology and pharmaceutical companies for advancing its pipeline candidates. PTC Therapeutics is headquartered in South Plainfield, New Jersey, the US.

PTC Therapeutics Inc (PTCT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PTC Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

PTC Therapeutics Acquires US Rights to Emflaza from Marathon Pharma 12

Venture Financing 14

Agilis Biotherapeutics Raises USD 8 Million In Venture Financing 14

Agilis Biotherapeutics Raises USD8 Million in Venture Financing 15

PTC Therapeutics Raises USD4.5 Million in Financing 16

PTC Therapeutics Raises USD 60 Million In Venture Financing 17

PTC Therapeutics Raises USD 2 Million In Venture Financing 19

Ptc Therapeutics Raises USD 30 Million In Venture Financing 20

Partnerships 22

PTC Therapeutics Enters into Agreement with CHDI Foundation 22

Agilis Biotherapeutics and Gene Therapy Research Institution Form Joint Venture 23

Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 24

Agilis Biotherapeutics Enters into Agreement with T-TOP Clinical Research 25

PTC Therapeutics Enters into Agreement with University of Pennsylvania 26

Pint Pharma Enter into Co-operation Agreement with PTC Therapeutics 27

Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 28

Licensing Agreements 29

PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 29

Agilis Biotherapeutics Enters into Licensing Agreement with National Taiwan University 30

PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 31

Agilis Biotherapeutics Enters into Licensing Agreement with University of South Florida 32

Agilis Biotherapeutics Enters into Licensing Agreement with University of South Florida 33

Equity Offering 34

PTC Therapeutics Raises USD124.3 Million in Public Offering of Shares 34

Agilis Biotherapeutics Raises USD12.7 Million in Private Placement of Shares 36

PTC Therapeutics Raises USD125 Million in Public Offering of Shares 37

PTC Therapeutics Completes Public Offering Of Shares For USD 126.5 Million 39

PTC Therapeutics Completes IPO For USD 144.4 Million 41

PTC Therapeutics Raises USD53.9 Million in Private Placement of Preferred Shares 43

Debt Offering 44

PTC Therapeutics Raises USD150 Million in Private Placement of 3% Notes Due 2022 44

Acquisition 46

PTC Therapeutics Acquires Agilis Biotherapeutics 46

Sanofi May Acquire PTC Therapeutics 47

PTC Therapeutics Inc-Key Competitors 48

PTC Therapeutics Inc-Key Employees 49

PTC Therapeutics Inc-Locations And Subsidiaries 50

Head Office 50

Other Locations & Subsidiaries 50

Recent Developments 52

Financial Announcements 52

Nov 05, 2018: PTC Therapeutics reports third quarter 2018 financial results and provides a corporate update 52

Aug 07, 2018: PTC Therapeutics reports second quarter 2018 financial results and provides a corporate update 54

May 09, 2018: PTC Therapeutics Reports First Quarter 2018 Financial Results and Provides a Corporate Update 56

Mar 06, 2018: PTC Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results 58

Jan 08, 2018: PTC Therapeutics Provides Corporate Update and Outlines 2018 Strategic Priorities 60

Nov 02, 2017: PTC Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update 61

Aug 08, 2017: PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update 63

May 08, 2017: PTC Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update 65

Mar 16, 2017: PTC Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 66

Jan 09, 2017: PTC Therapeutics Provides Corporate Update and Outlines 2017 Strategic Priorities to Maximize the Global Value of Translarna and Advance its Innovative Pipeline 68

Corporate Communications 69

Jul 24, 2017: PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development 69

Jun 05, 2017: PTC Therapeutics Announces Executive Promotions 70

Apr 10, 2017: PTC Therapeutics Announces Departure of Chief Financial Officer, Shane Kovacs 71

Government and Public Interest 72

Feb 13, 2018: PTC Therapeutics Launches Fourth Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy 72

Feb 08, 2017: PTC Therapeutics Announces Third Annual STRIVE Grant Award Program for Duchenne Muscular Dystrophy 73

Product News 74

05/14/2018: Agilis Biotherapeutics Announces Data Presentations on AADC Deficiency at the American Society of Gene and Cell Therapy 2018 Annual Meeting 74

05/11/2017: Agilis Biotherapeutics Announces Presentation of Five Year Follow-Up Data of Gene Therapy Treatment for AADC Deficiency 76

05/10/2017: Agilis Biotherapeutics Announces Presentation of Data from Phase I/II Trial for Treatment of AADC Deficiency 77

04/24/2018: Agilis Biotherapeutics Presents Platform Paper on AADC Deficiency Gene Therapy at American Academy of Neurology Annual Meeting 78

Product Approvals 79

Oct 31, 2017: Agilis Biotherapeutics Announces Orphan Product Designation Approval in Europe for the Treatment of Friedreich Ataxia 79

Feb 09, 2017: FDA Approves EMFLAZA (deflazacort) Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older 80

Clinical Trials 81

Oct 03, 2017: Agilis Biotherapeutics Updates on Progress in CNS Gene Therapy Programs 81

Sep 06, 2017: Agilis Biotherapeutics Updates Progress of its CNS Gene Therapy for AADC Deficiency 83

Other Significant Developments 84

Jun 25, 2018: Decode Duchenne Announces 1,000th Patient Application 84

Appendix 85

Methodology 85

About GlobalData 85

Contact Us 85

Disclaimer 85


List Of Figure

List of Figures

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

PTC Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

PTC Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

PTC Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

PTC Therapeutics Acquires US Rights to Emflaza from Marathon Pharma 12

Agilis Biotherapeutics Raises USD 8 Million In Venture Financing 14

Agilis Biotherapeutics Raises USD8 Million in Venture Financing 15

PTC Therapeutics Raises USD4.5 Million in Financing 16

PTC Therapeutics Raises USD 60 Million In Venture Financing 17

PTC Therapeutics Raises USD 2 Million In Venture Financing 19

Ptc Therapeutics Raises USD 30 Million In Venture Financing 20

PTC Therapeutics Enters into Agreement with CHDI Foundation 22

Agilis Biotherapeutics and Gene Therapy Research Institution Form Joint Venture 23

Agilis Biotherapeutics Partners with National Center for Accelerating Translational Sciences 24

Agilis Biotherapeutics Enters into Agreement with T-TOP Clinical Research 25

PTC Therapeutics Enters into Agreement with University of Pennsylvania 26

Pint Pharma Enter into Co-operation Agreement with PTC Therapeutics 27

Agilis Biotherapeutics Enters Into Co-Development Agreement With Intrexon 28

PTC Therapeutics Enters into Licesing Agreement with Akcea Therapeutics 29

Agilis Biotherapeutics Enters into Licensing Agreement with National Taiwan University 30

PTC Therapeutics Enters into Licensing Agreement with Massachusetts General Hospital 31

Agilis Biotherapeutics Enters into Licensing Agreement with University of South Florida 32

Agilis Biotherapeutics Enters into Licensing Agreement with University of South Florida 33

PTC Therapeutics Raises USD124.3 Million in Public Offering of Shares 34

Agilis Biotherapeutics Raises USD12.7 Million in Private Placement of Shares 36

PTC Therapeutics Raises USD125 Million in Public Offering of Shares 37

PTC Therapeutics Completes Public Offering Of Shares For USD 126.5 Million 39

PTC Therapeutics Completes IPO For USD 144.4 Million 41

PTC Therapeutics Raises USD53.9 Million in Private Placement of Preferred Shares 43

PTC Therapeutics Raises USD150 Million in Private Placement of 3% Notes Due 2022 44

PTC Therapeutics Acquires Agilis Biotherapeutics 46

Sanofi May Acquire PTC Therapeutics 47

PTC Therapeutics Inc, Key Competitors 48

PTC Therapeutics Inc, Key Employees 49

PTC Therapeutics Inc, Other Locations 50

PTC Therapeutics Inc, Subsidiaries 50

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

PTC Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.